Search
Dermata Therapeutics Inc
DRMAAdd to Watchlist
1.340USD
-0.040-2.90%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
5.39MMarket Cap
LossP/E TTM
More Details of Dermata Therapeutics Inc Company
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Dermata Therapeutics Inc Info
Ticker SymbolDRMA
Company nameDermata Therapeutics Inc
IPO dateAug 13, 2021
CEOProehl (Gerald T)
Number of employees8
Security typeOrdinary Share
Fiscal year-endAug 13
Address3525 Del Mar Heights Rd., #322
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18582230882
Websitehttps://www.dermatarx.com/
Ticker SymbolDRMA
IPO dateAug 13, 2021
CEOProehl (Gerald T)
Company Executives of Dermata Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
612.85K
-13.05%
Ms. Kyri K. Van Hoose
Ms. Kyri K. Van Hoose
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
130.42K
--
Mr. David F. Hale
Mr. David F. Hale
Lead Independent Director
Lead Independent Director
8.14K
-0.02%
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Director
Independent Director
25.00
-4.00%
Dr. Christopher J. Nardo, Ph.D.
Dr. Christopher J. Nardo, Ph.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
11.00
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Independent Director
Independent Director
1.00
-1100.00%
Dr. Maria Bedoya Toro Munera, Ph.D.
Dr. Maria Bedoya Toro Munera, Ph.D.
Senior Vice President - Regulatory Affairs & Quality Assurance
Senior Vice President - Regulatory Affairs & Quality Assurance
--
--
Dr. Steven J. Mento, Ph.D.
Dr. Steven J. Mento, Ph.D.
Independent Director
Independent Director
--
--
Ms. Mary M. Fisher
Ms. Mary M. Fisher
Independent Director
Independent Director
--
--
Dr. Andrew S. Sandler, M.D.
Dr. Andrew S. Sandler, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
612.85K
-13.05%
Ms. Kyri K. Van Hoose
Ms. Kyri K. Van Hoose
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
130.42K
--
Mr. David F. Hale
Mr. David F. Hale
Lead Independent Director
Lead Independent Director
8.14K
-0.02%
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Director
Independent Director
25.00
-4.00%
Dr. Christopher J. Nardo, Ph.D.
Dr. Christopher J. Nardo, Ph.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
11.00
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Independent Director
Independent Director
1.00
-1100.00%
FAQs
Who are the top five shareholders of Dermata Therapeutics Inc?
The top five shareholders of Dermata Therapeutics Inc are: Mr. Gerald T. (Gerry) Proehl
How many institutions hold shares of Dermata Therapeutics Inc (DRMA)?
As of 2026Q1, 19 institutions hold shares of Dermata Therapeutics Inc, with a combined market value of approximately 265.70K, accounting for 6.61% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 14057.00.